(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.